Development of a core outcome set for breast cancer-related lymphedema: a Delphi study

被引:3
|
作者
Doubblestein, David [1 ]
Koehler, Linda [2 ]
Anderson, Elizabeth [3 ]
Scheiman, Nicole [4 ]
Stewart, Paula [5 ]
Schaverien, Mark [6 ]
Armer, Jane [3 ]
机构
[1] AT Still Univ, Dept Phys Therapy, Mesa, AZ 85206 USA
[2] Univ Minnesota, Dept Rehabil Med, Minneapolis, MN USA
[3] Univ Missouri, Sinclair Sch Nursing, Columbia, MO USA
[4] Huntington Univ, Occupat Therapy Assistant Program, Huntington, IN USA
[5] Parkridge Med Ctr Wound Care, Parkridge Med Ctr, Lymphedema Clin, Chattanooga, TN USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Plast Surg, Div Surg, Houston, TX USA
关键词
Breast cancer-related lymphedema; Core outcome set; Outcome measures; QUALITY-OF-LIFE; DECONGESTIVE THERAPY; SECONDARY LYMPHEDEMA; ARM LYMPHEDEMA;
D O I
10.1007/s10549-024-07262-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeFor breast cancer survivors (BCS) living with breast cancer-related lymphedema (BCRL), what outcome domains (OD) should be measured to assess the burden of the disease and efficacy of interventions? A Core Outcome Set (COS) that promotes standardized measurement of outcomes within the constraints of time influenced by work environments is essential for patients and the multidisciplinary professionals that manage and research BCRL.MethodsUsing Delphi methodology, a multidisciplinary group of BCRL experts (physical and occupational therapists, physicians, researchers, physical therapist assistants, nurses, and massage therapist) completed two waves of online surveys. BCRL expert respondents that completed the first survey (n = 78) had an average of 26.5 years in practice, whereas, respondents who completed the second survey (n = 33) had an average of 24.9 years. ODs were included in the COS when consensus thresholds, ranging from 70% to 80%, were met.ResultsA total of 12 ODs made up the COS. Reaching a minimum consensus of 70%; volume, tissue consistency, pain, patient-reported upper quadrant function, patient-reported health-related quality of life, and upper extremity activity and motor control were recommended at different phases of the BCRL continuum in a time-constrained environment. Joint function, flexibility, strength, sensation, mobility and balance, and fatigue met an 80% consensus to be added when time and resources were not constrained.ConclusionThe COS developed in this study thoroughly captures the burden of BCRL. Using this COS may reduce selective reporting, inconsistency in clinical use, and variability of reporting across interdisciplinary healthcare fields, which manage or research BCRL.
引用
收藏
页码:359 / 370
页数:12
相关论文
共 50 条
  • [1] Development of a core outcome set for breast cancer-related lymphedema: a Delphi study
    David Doubblestein
    Linda Koehler
    Elizabeth Anderson
    Nicole Scheiman
    Paula Stewart
    Mark Schaverien
    Jane Armer
    Breast Cancer Research and Treatment, 2024, 205 : 359 - 370
  • [2] Development of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains
    David Doubblestein
    Linda Koehler
    Elizabeth Anderson
    Nicole Scheiman
    Paula Stewart
    Mark Schaverien
    Jane Armer
    Breast Cancer Research and Treatment, 2024, 205 : 439 - 449
  • [3] Development of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains
    Doubblestein, David
    Koehler, Linda
    Anderson, Elizabeth
    Scheiman, Nicole
    Stewart, Paula
    Schaverien, Mark
    Armer, Jane
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 205 (03) : 439 - 449
  • [4] Development and validation of a nomogram for breast cancer-related lymphedema
    Jiang, Qihua
    Hu, Hai
    Liao, Jing
    Li, Zhi-hua
    Tan, Juntao
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [5] Use of Outcome Measures by Certified Lymphedema Therapists With Survivors of Breast Cancer With Breast Cancer-Related Lymphedema
    Doubblestein, David Aaron
    Spinelli, Bryan A.
    Goldberg, Allon
    Larson, Cathy A.
    Yorke, Amy M.
    REHABILITATION ONCOLOGY, 2023, 41 (01) : 34 - 46
  • [6] Prevention of Breast Cancer-Related Lymphedema
    McEvoy, Maureen P.
    Ravetch, Ethan
    Patel, Gunj
    Fox, Jana
    Feldman, Sheldon
    CLINICAL BREAST CANCER, 2021, 21 (02) : 128 - 142
  • [7] Taxanes and Breast Cancer-Related Lymphedema
    Najafali, Daniel
    Siotos, Charalampos
    Kokosis, George
    JOURNAL OF SURGICAL ONCOLOGY, 2024,
  • [8] Management of Breast Cancer-Related Lymphedema
    Donmez, Ayse Arikan
    Kapucu, Sevgisun
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2016, 31 (04): : 138 - 148
  • [9] Breast cancer-related lymphedema and treatment
    Horvath Anna
    Redling Marianna
    ORVOSI HETILAP, 2022, 163 (23) : 902 - 910
  • [10] Development and Validation of a Risk Model for Breast Cancer-Related Lymphedema
    Kwan, Jennifer Yin Yee
    Famiyeh, Petra
    Su, Jie
    Xu, Wei
    Kwan, Benjamin Yin Ming
    Jones, Jennifer M.
    Chang, Eugene
    Yip, Kenneth W.
    Liu, Fei-Fei
    JAMA NETWORK OPEN, 2020, 3 (11)